55岁及以上个体多发性硬化症的管理:综合性综述
Óscar Fernández1,2, Per Soelberg Sörensen3,4, Giancarlo Comi5,6
1Departament of Pharmacology, Faculty of Medicine; Institute of Biomedical Research of Malaga (IBIMA), Regional University Hospital of Malaga, Malaga, Spain.
Frontiers in immunology
|April 22, 2024
概括
在55岁以上的成年人中管理多发性硬化症 (MS) 需要解决衰老,并发性疾病和不断变化的疾病形式. 本综述涵盖了老年多发性硬化患者的治疗方法,非药物治疗和个性化策略.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 免疫学 免疫学 免疫学
背景情况:
- 在老年人 (55岁以上) 中,多发性硬化症 (MS) 管理面临着独特的挑战.
- 衰老,并发性疾病,免疫衰变和MS病理生理学之间有复杂的相互作用.
- 在这个人口群体中观察到MS的发病率和流行率增加.
研究的目的:
- 为老年多发性硬化患者提供疾病修饰治疗 (DMT) 的最新审查.
- 探索新兴疗法,包括布鲁顿氨酸激酶 (BTK) 抑制剂,复髓化和神经保护剂.
- 检查非药物干预和以患者为中心的护理模式.
主要方法:
- 对现有和新兴多发性硬化症疗法的综合文献综述.
- 对老年人群中DMT的疗效和安全数据的分析.
- 评估非药理学方法和护理协调策略.
主要成果:
- 患有多发性硬化症的老年人往往呈现出渐进的表型和多发性疾病.
- 现有的DMT需要仔细考虑这个年龄组的安全性和有效性.
- 新兴的治疗方法和非药物干预措施提供了新的管理途径.
结论:
- 对老年多发性硬化患者来说,个性化管理,持续监测和预先护理规划至关重要.
- 优化DMT,包括启动,降级和停止,是必不可少的.
- 需要包括的临床研究设计,以改善对这个不断增长的人口的护理.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Aging
49
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
49
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Cognitive Development During Adulthood
94
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
94
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468


